Good MorningStocks delivered mixed results on Wednesday. The Dow had a second down day. However, the NASDAQ and S&P 500 exchanges both turned positive after Tuesday’s decline.
Investors were waiting to hear what Fed chair Jerome Powell had to say, and they weren’t disappointed. Powell reaffirmed his view that the economy was “a ways off” from a point where the Fed would consider tightening its monetary policy.
There was also good news on the stalled infrastructure bill. A select group of Republicans is now indicating that there may be a path forward.
And after the market closed, Facebook delivered a strong earnings report. However, the stock of the social media giant plunged after it lowered its guidance on expectations of a significant slowdown in its pace of revenue growth for the rest of the year.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Markets | |
In your head, you've always known you'll make it to the millionaire club. However, getting to $1 million and beyond has proven more difficult than you thought (despite reading every book related to "The Millionaire Next Door" that ever existed).
Wealthy people often say, "My first $1 million was... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Healthcare | | Canadian cannabis producer Tilray (NASDAQ: TLRY), which has been in a steep consolidation since mid-February, posted fourth-quarter income of $0.18 per share on revenue of $142.2 million.
Both those numbers represent year-over-year gains over the same quarter last year. Earnings topped views; howe... Read the Full Story |
|
Communication Services | | Digital advertising stocks are perhaps one of the most intriguing areas of the tech space for investors to consider at this time. With people using their devices like smartphones, personal computers, and connected televisions more than ever thanks to the pandemic, the companies that offer marketers ... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Industrials | | Trucking company Old Dominion Freight Line (NASDAQ: ODFL) gapped down Wednesday following its second-quarter earnings report. However, in mid-session, the stock reversed much of the early loss and was near the high of its daily trading range.
The company reported earnings of $2.21 per share, up 85%... Read the Full Story |
|
Consumer Staples | |
There are stocks that lend well to day trading. And then there are those you just hang on to for a while.In the case of younger investors such as Millennials, there are plenty of people who do both. For some, a taxable brokerage account serves as the ‘sandbox’ for short-term trading wh... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Staples | | Plant-based food producer Tattooed Chef, Inc. (NASDAQ: TTCF) stock has been underperforming the markets as shares are down (-15%) for 2021. The natural, clean, and sustainable plant-based food revolution is still strong, and the Company has a pipeline of over 250 ideas for innovation. The Company is... Read the Full Story |
|
Markets | |
Six Flags (NYSE:SIX) held up well during the pandemic. Considering that most of the company’s theme parks were shut down for a good part of 2020, investors can’t be upset about a 257% gain since the stock tumbled to $11.80 a share in March 2020. And, SIX stock has outperformed the S&am... Read the Full Story |
|
Consumer Discretionary | |
A year ago, it would’ve been tough to convince anyone that a restaurant stock would be a good earnings play. My how the tables have turned. Literally.
With many restaurant chains welcoming back dining room customers, fuller tables are expected to lead to some more appetizing second-quarter ... Read the Full Story |
|
Consumer Discretionary | |
Haverty Furniture Company Sustains Growth
If you were wondering if Haverty Furniture Company (NYSE: HVT) is still a good bUy the answer is a resounding yes. The company is one of the best run in an industry fueled by pandemic trends and sustained by high demand for housing and lifestyle improveme... Read the Full Story |
|
Consumer Discretionary | | Iconic clothing brand Levi Strauss & Co. (NYSE: LEVI) stock is performing strong during the reopening phase post-pandemic. The Company has clearly emerged from the pandemic as a stronger and more e-commerce oriented organization. The acceleration of COVID vaccinations should continue to build mo... Read the Full Story |
|
The Early Bird Stock Of The Day Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
